These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 33832817)
1. Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies. Stanojevic M; Hont AB; Geiger A; O'Brien S; Ulrey R; Grant M; Datar A; Lee PH; Lang H; Cruz CRY; Hanley PJ; Barrett AJ; Keller MD; Bollard CM Cytotherapy; 2021 Aug; 23(8):694-703. PubMed ID: 33832817 [TBL] [Abstract][Full Text] [Related]
2. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Rezvani K; Yong AS; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ Blood; 2009 Mar; 113(10):2245-55. PubMed ID: 18988867 [TBL] [Abstract][Full Text] [Related]
3. Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma. Frøsig TM Dan Med J; 2015 Aug; 62(8):B5144. PubMed ID: 26239596 [TBL] [Abstract][Full Text] [Related]
4. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381 [TBL] [Abstract][Full Text] [Related]
6. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612 [TBL] [Abstract][Full Text] [Related]
7. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437 [TBL] [Abstract][Full Text] [Related]
8. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146 [TBL] [Abstract][Full Text] [Related]
9. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604 [TBL] [Abstract][Full Text] [Related]
10. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Kobayashi H; Wood M; Song Y; Appella E; Celis E Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652 [TBL] [Abstract][Full Text] [Related]
11. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM Front Immunol; 2023; 14():1121973. PubMed ID: 37026005 [TBL] [Abstract][Full Text] [Related]
12. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590 [TBL] [Abstract][Full Text] [Related]
13. Broadening the repertoire of melanoma-associated T-cell epitopes. Frøsig TM; Lyngaa R; Met Ö; Larsen SK; Donia M; Svane IM; Thor Straten P; Hadrup SR Cancer Immunol Immunother; 2015 May; 64(5):609-20. PubMed ID: 25854582 [TBL] [Abstract][Full Text] [Related]
14. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095 [TBL] [Abstract][Full Text] [Related]
15. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663 [TBL] [Abstract][Full Text] [Related]
16. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729 [TBL] [Abstract][Full Text] [Related]
17. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675 [TBL] [Abstract][Full Text] [Related]
18. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations. Meng Z; Wang Y; Zhang G; Ke Y; Yan Y; Wu L; Huang Q; Zeng G; Wang Y; Ying H; Jiao S J Immunother; 2011 Sep; 34(7):525-34. PubMed ID: 21760531 [TBL] [Abstract][Full Text] [Related]
19. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401 [TBL] [Abstract][Full Text] [Related]
20. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. Kissick HT; Sanda MG; Dunn LK; Arredouani MS PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]